Aphios

Aphios develops differentiated therapeutics through green manufacturing, nanotechnology drug delivery, and pathogen-safety platforms, operating as a phase 3-ready, ESG-focused biotech company with 87 issued U.S. and international patents, 40 pending applications, $20M in NIH grants, and a $1.6B peak-sales asset. The company operates through a hybrid business model combining proprietary therapeutic development with technology licensing, structured across multiple Special Purpose Vehicles. Aphios Pharma LLC develops cannabis-based drugs using patented nanotechnology for sustained cannabinoid release, targeting chronic conditions including pain, anxiety, addiction, and MS in a $93B market. Zindol LLC develops ginger extract therapy for chemotherapy-induced and pregnancy-related nausea and vomiting in a $3.4B market. Aphios International LLC develops CFI pathogen reduction technology for biologics and plasma in a $2.5B market. Amylon LLC commercializes nanoencapsulated Bryoids for Alzheimer's and dementia. The company's therapeutic pipeline spans oncology (Taxosomes, Camposomes, Dermos), infectious diseases (HIV therapeutics, anti-influenza, vaccine adjuvants), CNS disorders (CBD nanotherapies for OUD, CIPNP, anxiety, MS, epilepsy), and diabetes. Technology platforms include SuperFluids for drug manufacturing, CFN/PNS/PNP for drug delivery, and CFI for pathogen safety. Founded in 1993 and headquartered in North Reading, Massachusetts, Aphios has received funding from SBIR, Citizens Bank, National Heart Lung and Blood Institute, NIH, and HHS.